945749-71-3

Basic information

• Product Name: 4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid
• Synonyms: 4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid;4-(2-{[4-(4-Morpholinyl)phenyl]amino}-4-pyrimidinyl)benzoic acid;Benzoic acid, 4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
• CAS NO: 945749-71-3
• Molecular Formula: C₂₁H₂₀N₄O₃
• Molecular Weight: 376.4085
• Mol File: 945749-71-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid(945749-71-3)
• EPA Substance Registry System: 4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid(945749-71-3)

Safety Data

• Hazardous Substances Data: 945749-71-3(Hazardous Substances Data)

Usage

General Description

4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid is a chemical compound with the molecular formula C22H20N4O4. It is classified as a benzoic acid derivative and contains a pyrimidine ring with a phenylamino group and a morpholine group attached to it. 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid is likely to have potential pharmacological properties due to its structural features, making it a target for drug development or medicinal research. The chemical structure of 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid can be used as a scaffold for designing new drugs with specific biological activities, such as anti-cancer, anti-inflammatory, or anti-microbial effects, or as a chemical probe for studying biological pathways and mechanisms.

Upstream product

• 499195-60-7 4-(4-carboethoxyphenyl)-2-chloropyrimidine 
• 4334-88-7 p-ethoxycarbonylphenylboronic acid 
• 1026029-33-3 4-(2-chloropyrimidin-4-yl) methyl benzoate 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 100-00-5 4-chlorobenzonitrile 
• 2524-67-6 4-morpholino-4-yl-phenylamine 
• 10389-51-2 1-morpholino-4-nitrobenzene 
• 1056634-62-8 ethyl 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoate 
• 701215-21-6 methyl 4-[3-(dimethylamino)-1-oxo-2-propen-1-yl]benzoate 
• 114431-72-0 (E)-methyl 4-(3-(dimethylamino)acryloyl)benzoate 
• 3609-53-8 methyl 4-acetylbenzoate 
• 247234-41-9 1-(4-morpholinophenyl)guanidine 

Downstream Products

• 1056634-68-4 Momelotinib 
• 1619927-63-7 N-(cyano(d₂-methyl))-4-(2-(4-(morpholinophenyl)amino)pyrimidin-4-yl)benzamide 

Relevant articles and documents

Synthesis of Imidazoles and Oxazoles via a Palladium-Catalyzed Decarboxylative Addition/Cyclization Reaction Sequence of Aromatic Carboxylic Acids with Functionalized Aliphatic Nitriles

We herein report an efficient approach for the assembly of multiply substituted imidazoles and oxazoles in a single-step manner. These transformations are based on a decarboxylation addition and annulation of readily accessible aromatic carboxylic acids a

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections

Clinically, leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens. Herein, a novel therapeutic strategy was developed in which a small molecule can simultaneously treat leukemia and invasive fungal infections (IFIs). Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematological cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections. In particular, compound 20a, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections. This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.

A method for preparing Momelotinib JAK inhibitors (by machine translation)

The invention relates to a method for the synthesis of inhibitors JAK Momelotinib, chemical medicine, in the field of chemical engineering and technology. Comprises the following steps : (a) the 4 the aniline and morpholine- [...] 50% shan Jingan dissolve